Drug intelligence / Profile preview

LBP-AIEC01

Development stage: Preclinical
Lead developer: Locus Biosciences
Modality: Oncolytic Viruses → Oncolytic Therapeutics, CRISPR-Cas9 → CRISPR Systems → Programmable Nucleases → Gene Editing → Gene Therapies, Live Biotherapeutic Products → Microbiome Therapeutics

Overview

LBP-AIEC01 is an investigational engineered bacteriophage therapy developed by Locus Biosciences for the treatment of inflammatory bowel disease (IBD) and Crohn's disease. It is a precision medicine designed to selectively target and eliminate adherent-invasive E. coli (AIEC), a type of bacteria implicated in the pathogenesis of Crohn's disease. LBP-AIEC01 utilizes CRISPR-Cas3 technology to enhance the phage's natural lytic activity, leading to the destruction of the target bacteria. It is part of the company's pipeline of precision antibacterial therapeutics.

Beyond the preview

Go deeper on LBP-AIEC01.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on LBP-AIEC01.

Explore the full profile